In deze ADA-update vertelt internist Nordin Hanssen over Retatrutide, een nieuwe single molecule die receptor affiniteit toont voor GLP-1, GIP en glucagon. Bekijk de besproken fase 2 studies hier:
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial – https://www.nejm.org/doi/pdf/10.1056/NEJMoa2301972
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel group, phase 2 trial conducted in the USA – https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
